AVAV's March Plunge Confirms Contract Turmoil and Execution Risks

What happened

AeroVironment's stock crashed 27% in March after Q3 results revealed the U.S. Space Force terminated its BADGER contract, part of the SCAR program, exposing severe backlog and execution issues. This termination triggered a $151 million goodwill impairment and the removal of $1.4 billion in unfunded backlog options, directly undermining investor trust in the company's growth narrative. Q3 performance was dismal, with a 27% adjusted gross margin, negative operating income, and free cash flow, highlighting operational inefficiencies beyond contract woes. Management cited a $40 million high-margin revenue slip to Q4, compounding concerns over shipment reliability, while internal control weaknesses remain unresolved, adding to execution risks. Although the company can reapply for the contract, this event underscores AVAV's fragility in converting awards to stable revenue, demanding near-term proof of margin recovery and backlog quality.

Implication

The contract termination reinforces AVAV's vulnerability to program-specific shocks, necessitating skepticism toward unfunded backlog and option-heavy awards until funded orders materialize. Negative cash flow and earnings in Q3 signal that growth isn't translating to profitability, challenging the sustainability of elevated multiples amid operational hiccups. Persistent shipment slips and unresolved control weaknesses risk delaying any margin rebound, keeping stock pressure high until remediation is demonstrably effective. Management's reapplication possibility offers little near-term relief, as recompete timelines and outcomes are uncertain, exacerbating investor overhang and volatility. Until AVAV shows consistent delivery cadence and backlog replenishment post-SCAR, the stock lacks a margin of safety, aligning with the report's POTENTIAL SELL rating and unattractive entry points.

Thesis delta

This news does not shift the core thesis but intensifies its bearish elements, as the contract termination validates the report's warnings about backlog credibility and execution risks. Investors must now see concrete evidence in Q4, such as the shipped $40 million slip and margin recovery to low-30s%, to avoid further downside, with any optimism on reapplication being speculative without immediate funding clarity.